Oncolytics Biotech Inc. (Oncolytics) is a Canada-based development-stage company. The Company is focused on the research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from reovirus. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. The Company’s clinical trial program has included human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. The Company has two subsidiaries: Oncolytics Biotech (Barbados) Inc. (OBB) and Valens Pharma Ltd.